atezolizumab

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Trade Name(s):

Tecentriq

NCI Definition [1]:

A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, MPDL3280A also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of MPDL3280A is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).

Biomarker-Directed Therapies

Atezolizumab can be used in the treatment of non-squamous non-small cell lung carcinoma, breast carcinoma, melanoma, and non-small cell lung carcinoma. PD-L1 Expression, PD-L1 High Expression, and BRAF are the most frequent biomarker inclusion criteria for use of atezolizumab [2].

Non-Small Cell Lung Carcinoma +

Disease is predicted to be sensitive to atezolizumab: -

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

PD-L1 Expression, PD-L1 High Expression

Sample must not match any of the following:

ALK Fusion, EGFR T790M

EGFR Sensitizing Mutations

Clinical Setting(s): Metastatic (FDA, NCCN)

Note: Approved for the first-line treatment of adult patients with metastatic NSCLC with high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no EGFR or ALK alterations.

Biomarker Criteria: Sample must match all of the following: Sample must match one or more of the following: PD-L1 Expression, PD-L1 High Expression Sample must not match any of the following: ALK Fusion, EGFR T790M EGFR Sensitizing Mutations	Clinical Setting(s): Metastatic (FDA, NCCN)
	Note: Approved for the first-line treatment of adult patients with metastatic NSCLC with high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no EGFR or ALK alterations.

Clinical Trials

View Clinical Trials for atezolizumab

Atezolizumab has been investigated in 291 clinical trials, of which 249 are open and 42 are closed. Of the trials investigating atezolizumab, 4 are early phase 1 (3 open), 63 are phase 1 (44 open), 46 are phase 1/phase 2 (38 open), 129 are phase 2 (116 open), 4 are phase 2/phase 3 (4 open), 44 are phase 3 (43 open), and 1 is phase 4 (1 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for atezolizumab clinical trials.

Non-small cell lung carcinoma, breast carcinoma, and malignant solid tumor are the most common diseases being investigated in atezolizumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Atezolizumab

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Atezolizumab

This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating atezolizumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:

TECENTRIQ, mpdl3280a, mpdl 328oa, mpdl328oa, atezolizumab, tecentriq, immunoglobulin g1, anti-(human cd antigen cd274) (human monoclonal mpdl3280a heavy chain), disulfide with human monoclonal mpdl3280a kappa-chain, dimer, ro5541267, mpdl 3280a, mpdl-3280a, atezolizumab (substance), anti-pd-l1 monoclonal antibody mpdl3280a, atezolizumab

Drug Categories [2]:

Anti-PD-L1 antibodies

Drug Target(s) [2]:

CD274

NCIT ID [1]:

C106250

SNOMED ID [1]:

R0-0036D

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Drugs /